Insmed Inc (INSM)vsZenas BioPharma, Inc. Common Stock (ZBIO)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
ZBIO
Zenas BioPharma, Inc. Common Stock
$22.19
+5.37%
HEALTHCARE · Cap: $1.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 5964% more annual revenue ($606.42M vs $10.00M). ZBIO leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
ZBIO
Avoid20
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -136.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : ZBIO
The strongest argument for ZBIO centers on Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : ZBIO
The primary concerns for ZBIO are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while ZBIO is a value play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ZBIO generates stronger free cash flow (-52M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 20/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Zenas BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?